单位：[1]Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol Oncol, Dept Med, New York, NY USA[2]Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA[3]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[4]Tongji Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[5]Tianjin Med Univ China, Hosp 2, Tianjin, Peoples R China[6]Carolina Urol Res Ctr, Myrtle Beach, SC USA[7]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[8]Asieris Pharmaceut Co Ltd, Shanghai, Peoples R China
第一作者单位：[1]Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol Oncol, Dept Med, New York, NY USA[2]Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA[3]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[4]Tongji Hosp, Wuhan, Peoples R China[5]Tianjin Med Univ China, Hosp 2, Tianjin, Peoples R China[6]Carolina Urol Res Ctr, Myrtle Beach, SC USA[7]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China[8]Asieris Pharmaceut Co Ltd, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Galsky Matt D.,Sfakianos John P.,Ye Ding-Wei,et al.ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC)[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Galsky, Matt D.,Sfakianos, John P.,Ye, Ding-Wei,Song, Xiaodong,Hu, Hailong...&Zhang, Mingming.(2023).ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Galsky, Matt D.,et al."ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC)".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学